Clin2
NCT07712692Possibly a fitNot yet recruiting

NWRD09 treatment for HPV16-related cervical high-grade lesions

High-grade Squamous Intraepithelial Lesion (HSIL)

Part of Cancer, Infections, Women’s health & pregnancy clinical trials.

This study tests an investigational drug called NWRD09 in women with high-grade cervical lesions caused by HPV16. The goal is to see if it can help eliminate the abnormal cells and reduce the risk of cervical cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
156 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • Women aged 18 to 65 years
  • Diagnosis of high-grade cervical lesion (HSIL) confirmed by a central lab
  • Positive test for HPV type 16
  • Adequate colposcopy exam (clear view of the abnormal area, or if not, a negative endocervical curettage)
  • Overall good health as shown by blood tests (e.g., hemoglobin, liver and kidney function)
  • Not pregnant or breastfeeding, and agree to use effective contraception if of childbearing age

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07047989Recruiting· Phase 1
NWRD09 for HPV-16 related cervical high-grade changes

This trial tests a new drug called NWRD09 for women with high-grade cervical cell changes (CIN 2/3) caused by HPV type 16. The goal is to see if the drug can help clear these abnormal cells without needing surgery.

Beijing
NCT07175662Recruiting· Phase 2
A new treatment for HPV-related high-grade cervical changes

This study tests a new treatment (NWRD08) for women with high-grade cervical changes (CIN 2/3) caused by HPV types 16 or 18. It aims to see if the treatment can help clear the abnormal cells and prevent them from becoming cancer.

Beijing, Beijing Municipality
NCT07710703Recruiting
Study of NWRD09 for persistent HPV 16 infection in women

This trial tests an experimental treatment called NWRD09 for women who have had a persistent HPV 16 infection for at least 12 months. The goal is to see if it can clear the virus and prevent cervical changes.

Beijing
NCT07710664Recruiting· Phase 1
New drug for persistent anal HPV16 infection

This trial tests a new drug (NWRD09) for people who have had HPV type 16 infection in the anal area for over a year. It aims to see if the drug can help clear the virus without causing serious side effects.

Beijing
NCT07668960Not yet recruiting· Phase 1/Phase 2
Study of BBM-C101 injection for cervical precancerous changes

This trial tests an injection called BBM-C101 for women with high-grade cervical precancerous lesions linked to HPV types 16 or 18. The goal is to see if it can safely help the body clear these abnormal cells and prevent them from becoming cancer.

Beijing, Beijing Municipality
NCT07536282Not yet recruiting· Phase 1/Phase 2
Studying NWRD09 for women with persistent HPV16 infection

This trial tests an experimental drug called NWRD09 for women with long-lasting HPV type 16 infection that hasn't gone away. The goal is to see if it can help clear the virus and prevent precancerous changes from becoming cancer.

New York, New York

Hear when a new High-grade Squamous Intraepithelial Lesion (HSIL) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.